



# Impact of Eteplirsen Treatment in Patients with Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a progressive muscle loss disorder



Muscular dystrophy




Healthy



DMD results in functional impairments and increased healthcare resource utilization (HRU)

The drug eteplirsen slows DMD progression and improves quality of life for patients



Can eteplirsen treatment reduce HRU among patients with DMD



A retrospective analysis of insurance claims data and electronic medical records of patients with DMD

Two-step matching of eteplirsen-treated and control group patients



Eteplirsen-treated cohort  
[n = 579]



Control cohort  
[n = 1296]



Exact matching of DMD stage and age



Propensity score matching of DMD-related HRU




Poisson regression analysis of HRU during annual follow-up


Hospital admissions (31%)




Emergency room visits (31%)




Pulmonary management (33%)




Impact of eteplirsen use on HRU



Cardiac management (21%)



Tracheostomies (86%)



Assisted ventilation (39%)

Eteplirsen treatment reduced dependence on healthcare resources and delayed muscle damage in patients with DMD